title: Acute lymphoblastic leukemia.
abstract: Precursor B-ALL (BCP-ALL) is associated with a good outcome in children. Cytogenetics is one of the gold standards for risk stratification for treatment that has contributed to improved survival. Although in T-ALL genetic analysis has not been used to guide therapy, it has contributed significantly to the understanding of the biology. State-of-the-art technologies in genomic and high throughput targeted sequencing are revealing novel genetic changes linked to biological and clinical features including outcome. A number of new biomarkers provide the potential for molecular targets for therapy with promise for further improvements in survival and quality of life for ALL sufferers.
authors: Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Level 5 Sir James Spence Institute, Royal Victoria Infirmary, Newcastle-upon-Tyne NE1 4LP, UK. christine.harrison@newcastle.ac.uk
authors: Christine J
authors: CJ
authors: Harrison
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis; D006801:Humans; D007223:Infant; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000235:genetics*; D011379:Prognosis